HRS-7535-202 Follow-up Study: A Long-term Evaluation of Safety, Tolerability, and Efficacy in Obese Subjects (Open-label, Extension Trial)
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Shandong Suncadia Medicine
- 08 Nov 2024 New trial record